Mononegavirales infectious disease

This study tests an experimental vaccine called RSVpreF in adults to see if it is safe and triggers a strong immune response against respiratory syncytial virus (RSV). Around 540 adults in India will receive either the vaccine or a placebo. Researchers will monitor for side effec…

This study tests an experimental vaccine from GSK that targets two respiratory viruses: RSV and hMPV. About 1,800 adults aged 18-80 will receive different doses to check safety and immune response. The goal is to see if a single shot can protect against both viruses, which can ca…

This study will test a new RSV vaccine in 60 adults aged 20 and older. Researchers want to understand how the vaccine triggers the immune system to create strong antibodies and memory T cells. The goal is to learn how to make RSV vaccines more effective.

This study tests a new mRNA vaccine called IN006 to see if it is safe and helps the body fight RSV, a virus that can cause serious breathing problems. About 200 healthy adults, both younger (18-59) and older (60-79), will receive one or two shots of the vaccine or a placebo. Rese…

This early-stage study tests a new vaccine (MKK900) against respiratory syncytial virus (RSV) in 120 healthy women aged 18 to 49. The main goal is to check if the vaccine is safe and triggers a strong immune response. Participants will receive either the new vaccine or an active …

This study will check how well a new RSV vaccine (RSVpreF) works when given to pregnant women in Brazil. Researchers will follow 5,000 infants up to 6 months old who are hospitalized or seen in clinics for respiratory illness. By comparing babies whose mothers got the vaccine to …

This early-stage trial will test the safety of a new RSV mRNA vaccine in 60 healthy adults aged 18 and older. Participants will receive either a low dose, high dose, or a placebo (saline) shot. The study aims to see if the vaccine causes any side effects, paving the way for large…

This study tests a new vaccine that protects against measles, mumps, rubella, and chickenpox (MMRV) in healthy children aged 15 months to 6 years. It compares the new vaccine to an already approved one (ProQuad) to see if it works as well and is safe. About 1,200 children will re…

This study looks at the real-world effectiveness of the RSV vaccine Abrysvo in adults. Researchers will analyze health records from over 290,000 people to compare those who got the vaccine with those who did not. The goal is to see if the vaccine reduces hospitalizations and othe…

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This study tests whether a single dose of the RSV vaccine (Arexvy) can reduce moderate-to-severe COPD flare-ups in people who have frequent attacks. Researchers will enroll 320 high-risk patients aged 50+ and follow them for one year. Half will get the vaccine plus standard care,…

This study tests an experimental oral drug called zelicapavir in 150 children aged 1 month to 3 years who have respiratory syncytial virus (RSV). The drug aims to stop the virus from multiplying and speed up recovery. Half the children will get the drug, half a placebo, and resea…

This study tests whether the RSV vaccine Abrysvo can help blood cancer patients who have had a stem cell transplant or CAR-T therapy build immunity against RSV. Researchers will measure antibody levels before and after vaccination in 30 adults. The goal is to see if the vaccine t…

This study evaluates two new diagnostic tests (FORTIFIEDx and DECIPHER) for detecting Ebola and Lassa viruses. Researchers will use stored blood and cheek swab samples from patients in Guinea to see how well these tests compare to the standard PCR method. The goal is to determine…

This study will test a new at-home diagnostic test that aims to detect five respiratory viruses—COVID-19, influenza A and B, RSV, and rhinovirus—from a single nose swab. About 2,000 people with cold or flu symptoms will provide samples in simulated home environments. The test's a…

This study tests whether a single dose of nirsevimab, an antibody that targets RSV, can prevent respiratory infections in Aboriginal and Torres Strait Islander children aged 6 months. Around 1,000 children will be randomly assigned to receive either the antibody or standard care.…

This study tests a new medicine called SIBP-A16 to see if it can safely prevent RSV in infants under 1 year old, including those born early. About 36 babies will receive either the new drug, a placebo, or an existing RSV drug. The main goal is to check for side effects and how th…

This study tests whether giving the Ervebo Ebola vaccine together with the antibody drug Inmazeb still works to protect people who may have been exposed to Ebola. The vaccine alone takes time to work, while antibodies act fast but might interfere with the vaccine. Researchers wil…

This study tests whether giving a vaccine plus an antibody drug right after high-risk Ebola contact can prevent the disease better than the vaccine alone. About 160 people who have had close contact with an Ebola patient (like touching body fluids or a dead body) will be randomly…

This study will check how well two RSV prevention methods work in real life: a vaccine given to pregnant women and an antibody shot given to newborns. Researchers will follow about 1,100 infants under 6 months old who are hospitalized with severe respiratory infections in Bogotá,…

This study looks at health records of babies born in Scotland to see if those whose mothers received the RSV vaccine (ABRYSVO) during pregnancy have fewer hospital visits for RSV. No new participants are enrolled; researchers will analyze existing data. The goal is to understand …

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This study follows 150 adults aged 60 and older who have a respiratory infection (flu, RSV, or COVID-19) or who test negative. Researchers will measure specific immune markers in the blood over 60 days to see how they change from early infection to recovery. The goal is to better…

This study will observe how many eligible infants in Czechia receive nirsevimab, a monoclonal antibody that helps prevent RSV, during their first RSV season. Researchers will survey parents of about 250 infants born between April 2025 and March 2027 to understand immunization rat…

This study will track which respiratory viruses—like flu, COVID-19, and RSV—are circulating in French primary care clinics each winter. Up to 25,000 patients with cold or flu symptoms will provide a saliva or nose swab sample. The goal is to monitor virus activity and help guide …

This study will observe 65 children, aged 1 to 24 months, hospitalized with bronchiolitis at Assiut University Hospital. Researchers will collect information on family, social, and medical factors to identify what makes the illness more severe. The goal is to help doctors predict…

This study looks at whether the types of bacteria in a child's gut can influence how sick they get from RSV, a common virus that can cause severe breathing problems in infants. Researchers in Vietnam will compare the gut bacteria and immune responses of 250 children with mild ver…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…

This study will observe up to 4,000 children under 5 years old who test positive for RSV and visit emergency departments in Turkey. Researchers will track how many children need to be admitted to the hospital or intensive care, and what treatments they receive. The goal is to bet…

This study follows 600 Chinese children who received standard vaccines against polio, measles, mumps, rubella, and hepatitis A. Researchers will test their blood to see if protective antibodies remain 5 years after vaccination. The goal is to understand how long vaccine protectio…

This study will track 10,000 adults in Hong Kong with respiratory symptoms to measure how often RSV causes illness and how severe it gets. Researchers will collect nose and throat samples and blood tests over several weeks. The goal is to fill knowledge gaps about RSV in adults a…

This study looks at whether giving iron to babies with low iron helps their bodies respond better to malaria and measles vaccines. About 324 infants in Kenya will take part. The goal is to see if treating iron deficiency can improve how well the vaccines protect them.

This study looks at 100 children to understand why measles causes short-term immune suppression but also lifelong immunity. Researchers will measure antibodies and immune cells before and after infection to see how measles changes the body's immune memory. The goal is to solve th…